Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2016, Article ID 8738959, 6 pages
http://dx.doi.org/10.1155/2016/8738959
Research Article

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

1Centro de Endocrinología, Rosario, Argentina
2Laboratorio de Biología Ósea, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina
3Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo (CICEMO), Buenos Aires, Argentina
4Mautalen Salud e Investigación, Buenos Aires, Argentina
5Laboratorio Osteoporosis y Enfermedades Metabólicas Óseas, INIGEM, UBA-CONICET, Hospital de Clínicas, Buenos Aires, Argentina
6Instituto de Diagnóstico e Investigaciones Metabólicas (IDIM), Cátedra de Osteología y Metabolismo Mineral, Universidad del Salvador, Buenos Aires, Argentina
7Consultorios Asociados de Endocrinología Dra. Laura Maffei, Buenos Aires, Argentina
8Centro de Endocrinología y Osteoporosis, La Plata, Argentina
9Hospital Milstein, Buenos Aires, Argentina
10Centro de Endocrinología y Osteopatías Médicas, Córdoba, Argentina
11Hospital Durand, Buenos Aires, Argentina
12Centro de Reumatología, Rosario, Argentina

Received 27 April 2016; Revised 24 June 2016; Accepted 12 July 2016

Academic Editor: Merry Jo Oursler

Copyright © 2016 A. Sánchez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Schurman, A. Bagur, H. Claus-Hermberg et al., “Guidelines for the diagnosis, prevention and treatment of osteoporosis, 2012,” Medicina (B Aires), vol. 73, no. 1, pp. 55–74, 2013. View at Google Scholar · View at Scopus
  2. S. R. Cummings, J. S. Martin, M. R. McClung et al., “Denosumab for prevention of fractures in postmenopausal women with osteoporosis,” The New England Journal of Medicine, vol. 361, no. 8, pp. 756–765, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. D. W. Dempster, C. L. Lambing, P. J. Kostenuik, and A. Grauer, “Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data,” Clinical Therapeutics, vol. 34, no. 3, pp. 521–536, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Baron, S. Ferrari, and R. G. Russell, “Denosumab and bisphosphonates: different mechanisms of action and effects,” Bone, vol. 48, no. 4, pp. 677–692, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Papapoulos, R. Chapurlat, C. Libanati et al., “Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension,” Journal of Bone and Mineral Research, vol. 27, no. 3, pp. 694–701, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. H. G. Bone, R. Chapurlat, M.-L. Brandi et al., “The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 11, pp. 4483–4492, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J. P. Brown, I. R. Reid, R. B. Wagman et al., “Effects of Up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension,” Journal of Bone and Mineral Research, vol. 29, no. 9, pp. 2051–2056, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Papapoulos, K. Lippuner, C. Roux et al., “The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study,” Osteoporosis International, vol. 26, no. 12, pp. 2773–2783, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Boonen, J. D. Adachi, Z. Man et al., “Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 6, pp. 1727–1736, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. J. P. Brown, R. L. Prince, C. Deal et al., “Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial,” Journal of Bone and Mineral Research, vol. 24, no. 1, pp. 153–161, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. D. L. Kendler, C. Roux, C. L. Benhamou et al., “Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy,” Journal of Bone and Mineral Research, vol. 25, no. 1, pp. 72–81, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. P. Brown, C. Roux, P. R. Ho et al., “Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate,” Osteoporosis International, vol. 25, no. 7, pp. 1953–1961, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. L. R. Brun, A. M. Galich, E. Vega et al., “Strontium ranelate effect on bone mineral density is modified by previous bisphosphonate treatment,” SpringerPlus, vol. 3, article 676, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. I. R. Reid, P. D. Miller, J. P. Brown et al., “Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies,” Journal of Bone and Mineral Research, vol. 25, no. 10, pp. 2256–2265, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. H. K. Genant, C. Libanati, K. Engelke et al., “Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab,” Bone, vol. 56, no. 2, pp. 482–488, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. K. E. S. Poole, G. M. Treece, A. H. Gee et al., “Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis,” Journal of Bone and Mineral Research, vol. 30, no. 1, pp. 46–54, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. R. M. Zebaze, C. Libanati, M. Austin et al., “Differing effects of denosumab and alendronate on cortical and trabecular bone,” Bone, vol. 59, pp. 173–179, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Seeman, P. D. Delmas, D. A. Hanley et al., “Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate,” Journal of Bone and Mineral Research, vol. 25, no. 8, pp. 1886–1894, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. T. M. Keaveny, M. R. McClung, H. K. Genant et al., “Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab,” Journal of Bone and Mineral Research, vol. 29, no. 1, pp. 158–165, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Ross, E. Samuels, K. Gairy, S. Iqbal, E. Badamgarav, and E. Siris, “A meta-analysis of osteoporotic fracture risk with medication nonadherence,” Value in Health, vol. 14, no. 4, pp. 571–581, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Freemantle, S. Satram-Hoang, E.-T. Tang et al., “Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women,” Osteoporosis International, vol. 23, no. 1, pp. 317–326, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. E. T. Middleton, S. A. Steel, M. Aye, and S. M. Doherty, “The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate,” Journal of Bone and Mineral Research, vol. 25, no. 3, pp. 455–462, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. P. D. Miller, N. Pannacciulli, J. P. Brown et al., “Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates,” The Journal of Clinical Endocrinology & Metabolism, 2016. View at Publisher · View at Google Scholar